Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome

Jialu Liu, Qian Shen, Li Xie, Jiyang Wang, Yaxuan Li, Jing Chen, Xiaoyan Fang, Xiaoshan Tang, Biyun Qian, Hong Xu, Jialu Liu, Qian Shen, Li Xie, Jiyang Wang, Yaxuan Li, Jing Chen, Xiaoyan Fang, Xiaoshan Tang, Biyun Qian, Hong Xu

Abstract

Introduction: Rituximab (RTX) effectively prevents relapses in patients with complicated steroid-sensitive nephrotic syndrome (SSNS). The 1-year relapse-free survival rate is approximately 30% in children after the first episode of SSNS treated with standardised corticosteroids. Whether the benefits of RTX extend to the first relapse are unknown. The efficacy and safety of RTX in the first episode of paediatric idiopathic nephrotic syndrome (RTXFIRPedINS) trial (NCT04783675) will assess its effect on the risk of subsequent relapse.

Methods and analysis: RTXFIRPedINS is an open-label, single-arm, multicentre trial targeting patients aged 1-18 years with a first episode of SSNS. All patients will receive standardised corticosteroid treatment for 12 weeks. A sample size of 44 patients provides 80% power to detect a 20% increase in the 1-year relapse-free rate, assuming a dropout rate of 10%. After obtaining informed consent and screening, eligible patients will be treated with a single intravenous infusion of 375 mg/m2 RTX within 1 week after achieving remission. Trimethoprim-sulfamethoxazole will be administered for 3 months after RTX administration to prevent Pneumocystis carinii infection. The follow-up period will be 1 year. The primary outcome is the 1-year relapse-free survival rate after RTX infusion. The secondary study outcomes are the number of days from the infusion of RTX to the occurrence of the first relapse, 6-month relapse-free survival rate, the B cell recovery time and treatment-related adverse events. Immunological factors will be studied as predictors of response.

Ethics and dissemination: This trial was approved by the Ethics Committee of the Children's Hospital of Fudan University and seven local ethics committees. We will publish our study results in peer-reviewed journals and present them at international scientific meetings.

Trial registration number: NCT04783675.

Keywords: clinical trials; immunology; paediatric nephrology.

Conflict of interest statement

Competing interests: HX received a grant from Shanghai Henlius Biotech, Inc [EK00000710].

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Schematic view of trial design.

References

    1. Banh THM, Hussain-Shamsy N, Patel V, et al. . Ethnic differences in incidence and outcomes of childhood nephrotic syndrome. Clin J Am Soc Nephrol 2016;11:1760–8. 10.2215/CJN.00380116
    1. Londeree J, McCracken CE, Greenbaum LA, et al. . Estimation of childhood nephrotic syndrome incidence: data from the Atlanta metropolitan statistical area and meta-analysis of worldwide cases. J Nephrol 2022;35:575–83. 10.1007/s40620-021-01108-9
    1. Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet 2018;392:61–74. 10.1016/S0140-6736(18)30536-1
    1. Trautmann A, Vivarelli M, Samuel S, et al. . IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2020;35:1529–61. 10.1007/s00467-020-04519-1
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group . KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 2021;100:S1–276. 10.1016/j.kint.2021.05.021
    1. Schijvens AM, Teeninga N, Dorresteijn EM, et al. . Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8 and 12 weeks regimen using an individual patient data meta-analysis. Eur J Pediatr 2021;180:2849–59. 10.1007/s00431-021-04035-w
    1. Veltkamp F, Rensma LR, Bouts AHM, et al. . Incidence and relapse of idiopathic nephrotic syndrome: meta-analysis. Pediatrics 2021;148:e2020029249. 10.1542/peds.2020-029249
    1. Iijima K, Sako M, Kamei K, et al. . Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. Pediatr Nephrol 2018;33:1449–55. 10.1007/s00467-017-3746-9
    1. Larkins NG, Liu ID, Willis NS, et al. . Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 2020;4:CD002290. 10.1002/14651858.CD002290.pub5
    1. Sinha R, Agrawal N, Xue Y, et al. . Use of rituximab in paediatric nephrology. Arch Dis Child 2021;106:1058–65. 10.1136/archdischild-2020-321211
    1. Rituximab from the first episode of idiopathic nephrotic syndrome (RIFIREINS). Available:
    1. Gargiulo A, Massella L, Ruggiero B, et al. . Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children. Kidney Int 2021;99:475–83. 10.1016/j.kint.2020.09.024
    1. Kitsou K, Askiti V, Mitsioni A, et al. . The immunopathogenesis of idiopathic nephrotic syndrome: a narrative review of the literature. Eur J Pediatr 2022;181:1395–404. 10.1007/s00431-021-04357-9
    1. Basu B, Angeletti A, Islam B, et al. . New and old anti-CD20 monoclonal antibodies for nephrotic syndrome. where we are? Front Immunol 2022;13:805697. 10.3389/fimmu.2022.805697
    1. Kopp JB, Anders H-J, Susztak K, et al. . Podocytopathies. Nat Rev Dis Primers 2020;6:68. 10.1038/s41572-020-0196-7

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever